LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-231 | CP466722 | 1.11 | uM | LJP5 | 3 | I09 | 72 | hr | 868 | 3022 | 3486 | 0.8668 | 0.8226 |
| MDA-MB-231 | Crizotinib | 1.11 | uM | LJP5 | 1 | A21 | 72 | hr | 868 | 1818 | 3486 | 0.5215 | 0.3628 |
| MDA-MB-231 | Crizotinib | 1.11 | uM | LJP5 | 2 | A21 | 72 | hr | 868 | 1804 | 3486 | 0.5174 | 0.3574 |
| MDA-MB-231 | Crizotinib | 1.11 | uM | LJP5 | 3 | A21 | 72 | hr | 868 | 1743 | 3486 | 0.4999 | 0.3341 |
| MDA-MB-231 | Momelotinib | 1.11 | uM | LJP5 | 1 | P09 | 72 | hr | 868 | 2109 | 3486 | 0.6049 | 0.4739 |
| MDA-MB-231 | Momelotinib | 1.11 | uM | LJP5 | 2 | P09 | 72 | hr | 868 | 2379 | 3486 | 0.6824 | 0.5771 |
| MDA-MB-231 | Momelotinib | 1.11 | uM | LJP5 | 3 | P09 | 72 | hr | 868 | 2331 | 3486 | 0.6686 | 0.5587 |
| MDA-MB-231 | Dasatinib | 1.11 | uM | LJP5 | 1 | D03 | 72 | hr | 868 | 513 | 3486 | 0.1471 | -0.1356 |
| MDA-MB-231 | Dasatinib | 1.11 | uM | LJP5 | 2 | D03 | 72 | hr | 868 | 488 | 3486 | 0.1400 | -0.1452 |
| MDA-MB-231 | Dasatinib | 1.11 | uM | LJP5 | 3 | D03 | 72 | hr | 868 | 491 | 3486 | 0.1408 | -0.1440 |
| MDA-MB-231 | Dasatinib | 1.11 | uM | LJP6 | 1 | I03 | 72 | hr | 868 | 475 | 3486 | 0.1362 | -0.1501 |
| MDA-MB-231 | Dasatinib | 1.11 | uM | LJP6 | 2 | I03 | 72 | hr | 868 | 477 | 3486 | 0.1368 | -0.1494 |
| MDA-MB-231 | Dasatinib | 1.11 | uM | LJP6 | 3 | I03 | 72 | hr | 868 | 572 | 3486 | 0.1641 | -0.1131 |
| MDA-MB-231 | Dovitinib | 1.11 | uM | LJP5 | 1 | E21 | 72 | hr | 868 | 1760 | 3486 | 0.5048 | 0.3406 |
| MDA-MB-231 | Dovitinib | 1.11 | uM | LJP5 | 2 | E21 | 72 | hr | 868 | 1755 | 3486 | 0.5034 | 0.3387 |
| MDA-MB-231 | Dovitinib | 1.11 | uM | LJP5 | 3 | E21 | 72 | hr | 868 | 1751 | 3486 | 0.5022 | 0.3372 |
| MDA-MB-231 | Enzastaurin | 1.11 | uM | LJP5 | 1 | D15 | 72 | hr | 868 | 3654 | 3486 | 1.0481 | 1.0640 |
| MDA-MB-231 | Enzastaurin | 1.11 | uM | LJP5 | 2 | D15 | 72 | hr | 868 | 3288 | 3486 | 0.9431 | 0.9242 |
| MDA-MB-231 | Enzastaurin | 1.11 | uM | LJP5 | 3 | D15 | 72 | hr | 868 | 3673 | 3486 | 1.0535 | 1.0713 |
| MDA-MB-231 | Erlotinib | 1.11 | uM | LJP5 | 1 | M21 | 72 | hr | 868 | 3325 | 3486 | 0.9537 | 0.9384 |
| MDA-MB-231 | Erlotinib | 1.11 | uM | LJP5 | 2 | M21 | 72 | hr | 868 | 3533 | 3486 | 1.0134 | 1.0178 |
| MDA-MB-231 | Erlotinib | 1.11 | uM | LJP5 | 3 | M21 | 72 | hr | 868 | 3158 | 3486 | 0.9058 | 0.8746 |
| MDA-MB-231 | Foretinib | 1.11 | uM | LJP5 | 1 | H09 | 72 | hr | 868 | 1339 | 3486 | 0.3841 | 0.1798 |
| MDA-MB-231 | Foretinib | 1.11 | uM | LJP5 | 2 | H09 | 72 | hr | 868 | 1329 | 3486 | 0.3812 | 0.1760 |
| MDA-MB-231 | Foretinib | 1.11 | uM | LJP5 | 3 | H09 | 72 | hr | 868 | 1343 | 3486 | 0.3852 | 0.1814 |